Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients

NCT03776695 is registered in ClinicalTrials.gov with Tychan Pte Ltd. as lead sponsor.

NCT NCT03776695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03776695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients
Lead sponsor
Tychan Pte Ltd.
Phase
Phase 1
Overall status
Withdrawn
Start date
October 9, 2018
Completion date
January 5, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of acute zika virus infection